(R)-Simurosertib, also known as (R)-TAK-931, is primarily investigated for its potential in cancer therapy. It functions as a selective inhibitor of cell division cycle 7 (CDC7) kinase, which plays a crucial role in DNA replication and cell cycle progression. By inhibiting CDC7, (R)-Simurosertib disrupts the replication process in cancer cells, leading to cell cycle arrest and ultimately inducing apoptosis. This mechanism makes it a promising candidate for targeting rapidly dividing cancer cells, particularly in solid tumors and hematologic malignancies. Research is ongoing to evaluate its efficacy in combination with other anticancer agents, aiming to enhance therapeutic outcomes and overcome resistance mechanisms in various cancer types.